Due: April 17, 2026
CPE CBRND is conducting essential market research for the Host-Directed Therapeutics (HD TX) program, a new initiative expected to launch in Fiscal Year 2027. This program is dedicated to identifying and advancing mature, threat-agnostic MCMs that strengthen the warfighter’s own physiological systems.
We are seeking collaboration with industry who are developing innovative solutions that modulate the body’s response to injury and infection, rather than targeting a specific pathogen.
Responding to this opportunity requires membership in the Medical CBRN Defense Consortium (MCDC). This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end up being right for you, we strongly encourage you to join, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.